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Abstract
Background: Seven transmembrane receptors (7TMRs) can adopt different active conformations facilitating a selective
activation of either G protein or b-arrestin-dependent signaling pathways. This represents an opportunity for development
of novel therapeutics targeting selective biological effects of a given receptor. Several studies on pathway separation have
been performed, many of these on the Angiotensin II type 1 receptor (AT1R). It has been shown that certain ligands or
mutations facilitate internalization and/or recruitment of b-arrestins without activation of G proteins. However, the
underlying molecular mechanisms remain largely unresolved. For instance, it is unclear whether such selective G protein-
uncoupling is caused by a lack of ability to interact with G proteins or rather by an increased ability of the receptor to recruit
b-arrestins. Since uncoupling of G proteins by increased ability to recruit b-arrestins could lead to different cellular or in vivo
outcomes than lack of ability to interact with G proteins, it is essential to distinguish between these two mechanisms.
Methodology/Principal Findings: We studied five AT1R mutants previously published to display pathway separation: D74N,
DRY/AAY, Y292F, N298A, and Y302F (Ballesteros-Weinstein numbering: 2.50, 3.49–3.51, 7.43, 7.49, and 7.53). We find that
D74N, DRY/AAY, and N298A mutants are more prone to b-arrestin recruitment than WT. In contrast, receptor mutants Y292F
and Y302F showed impaired ability to recruit b-arrestin in response to Sar
1-Ile
4-Ile
8 (SII) Ang II, a ligand solely activating the
b-arrestin pathway.
Conclusions/Significance: Our analysis reveals that the underlying conformations induced by these AT1R mutants most
likely represent principally different mechanisms of uncoupling the G protein, which for some mutants may be due to their
increased ability to recruit b-arrestin2. Hereby, these findings have important implications for drug discovery and 7TMR
biology and illustrate the necessity of uncovering the exact molecular determinants for G protein-coupling and b-arrestin
recruitment, respectively.
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Introduction
Seven transmembrane receptors (7TMR) are surface receptors
originally anticipated to signal only via heterotrimeric G proteins
to second messengers such as inositol trisphosphates and cyclic
AMP. It is now generally recognized that 7TMR signaling is much
more diverse and that receptors can activate signaling pathways
selectively mediated by multiple signaling conformations [1,2].
This phenomenon is believed to have physiological relevance,
hereby having widespread implications for both biological
understanding and drug development. However, the molecular
determinants underlying specific G protein or b-arrestin interac-
tions have yet to be determined. Hypothetically, impaired G
protein-dependent signaling and retained ability to interact with
b-arrestins could be mediated by two different types of
conformations: 1) One that lacks specific epitopes necessary for
activating G proteins, but retaining those for other pathways, or 2)
one that shows a preference for a G protein-independent pathway
such as b-arrestin, which then prevents G protein-dependent
signaling from occurring as illustrated in figure 1.
Activation of Family A 7TMRs most likely occurs through
concerted movements of the helical bundle, which ultimately
expose epitopes for intracellular signaling partners at the
cytoplasmic surface [3,4]. These movements are suggested to be
facilitated by conformational changes of amino acids in the
transmembrane domain that relieve structural constraints main-
taining the inactive state. Several of these residues are conserved
among Family A 7TMRs and include (numbered by the
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e14135Ballesteros-Weinstein method [5]) an aspartic acid in TM2 (2.50),
the DRY motif at the cytoplasmic part of TM3 (3.49–3.51), and
the NPXXY motif in TM7 (7.49–7.53) [3,4], see figure 2.
Functional selectivity proposes that receptors can adopt multiple
conformations upon ligand binding [6]. This possibility allows
different ligands and receptor mutants to selectively activate
downstream signaling pathways [7]. Several of the studies of such
functional selectivity or differential signaling have been conducted
on the Angiotensin (Ang) II type 1 receptor (AT1R). An example
of differential signaling is the recruitment of b-arrestins and the
successive activation of b-arrestin-dependent ERK1/2 activation.
This happens independently of G proteins and leads to different
temporal and spatial distributions of the activated kinases,
compared to the G protein-dependent response [7,8,9,10,11,12].
G protein-independent signaling provides exciting opportunities
in drug discovery. The AT1R is an important drug target due to
its role in the regulation of salt and water homeostasis and
cardiovascular functions [13,14]. This is illustrated by the fact that
AT1R antagonists or compounds inhibiting Ang II generation are
efficient in the treatment of hypertension, cardiac hypertrophy,
arrhythmias, and failure [14,15]. Studies suggest that selective
inhibition of Gaq/11 protein-dependent AT1R signaling may hold
Figure 1. Schematic presentation of possible mechanisms underlying differential activation. Hypothetically, a receptor mutant
selectively activating b-arrestin induced pathways could either be impaired in G protein-coupling (right) or show very strong interaction with b-
arrestins (left).
doi:10.1371/journal.pone.0014135.g001
Figure 2. Schematic presentation of the residues targeted for mutations in a snake diagram of the rAT1aR. Residues mutated in this
study are highlighted in black. These include the conserved DRY motif in the cytoplasmic part of TM3, the NPXXY motif in the cytoplasmic part of
TM7, and the aspartic acid in TM2. Residues removed by truncation are shown in grey. The conserved residues indexed to the number 50 in the
Ballesteros-Weinstein numbering scheme are highlighted in bold [5].
doi:10.1371/journal.pone.0014135.g002
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current un-biased treatment options [1]. Thus, determining the
molecular events underlying differential signaling is essential for
the design of selectively activating compounds. Several AT1R
residues reported to differentially affect signaling pathways upon
mutation are conserved polar residues in the transmembrane
domain suggested to be involved in the conformational changes
associated with receptor activation [12,16,17,18,19,20].
As mentioned above and illustrated in figure 1, G protein-
independent, b-arrestin-dependent signaling can hypothetically
occur through either lack of ability to recruit G proteins or a very
strong preference for b-arrestins. It has been shown that AT1R
desensitization and internalization appear very robust compared
to G protein activation [21]. Therefore, we speculated that at least
some differentially activated AT1R mutants might be particularly
prone to recruitment of b-arrestins. The AT1R interacts stably
with b-arrestin and co-translocates with the molecule into cytosolic
vesicles – a so-called Class B 7TMR pattern [22,23]. Truncation
or mutation of serine or threonine residues in the C-terminal tail
has been shown to disrupt this stable interaction with b-arrestin
leading to increased signaling through G protein-dependent
pathways [24,25,26,27,28,29].
In this study, we wanted to further investigate the conformational
backgrounds of five different AT1R mutants, previously shown to
be differentially activated in terms of loss of G protein-dependent
signaling, but retaining ability to recruit b-arrestins, activate
ERK1/2 and/or internalize – D74N, DRY/AAY, Y292F,
N298A, and Y302F (Ballesteros nomenclature: 2.50, 3.49–3.51,
7.43, 7.49, 7.53, see figure 2) [12,16,17,18,19,20,30,31]. To
evaluate the effect of the stable interaction with b-arrestins, we
truncated WT and mutant receptors after serine 331 (331D). Full
length and truncated WT and mutant receptors were characterized
in terms of inositol phosphate (IP) accumulation and b-arrestin2
recruitment. Our analysis revealed that receptor mutants D74N,
DRY/AAY, and N298A showed more potent b-arrestin2 recruit-
ment independently of G protein activation compared to WT
receptor. This suggests that these receptor mutants are more prone
to b-arrestin recruitment than WT. In contrast, receptor mutants
Y292F and Y302F showed impaired ability to recruit b-arrestin in
response to Sar
1-Ile
4-Ile
8 (SII) Ang II suggesting that these receptor
mutants represent conformational states distinct from both WT and
the other receptor mutants tested in this study. Truncation
improved ability to signal through Gaq/11 for all of the receptor
mutants tested. However, the DRY/AAY mutant remained
severely impaired in activation of G protein-dependent signaling.
Together, these results provide new insights to the molecular
determinants of differential signaling of the AT1R and further
support the existence of multiple signaling states.
Materials and Methods
Ligands
Ang II was from Sigma Aldrich. Sar
1-Ile
4-Ile
8 (SII) Ang II was
synthesized at the Cleveland Clinic, Lerner Research Institute,
OH, USA.
Recombinant DNA plasmids
Mutations, except DRY/AAY, were generated by PCR with the
WT rat AT1a as template using the QuickChange mutagenesis
protocol (Stratagene) or as described by Heckman et al., 2007
[32]. Truncation was made by PCR either in parallel with
mutation or separately on mutated background for constructs
generated by Quickchange mutagenesis (Primer for truncation:
59CGCTCTAGACTCGAGCTAAGACAGGCTTGAGTGG-
GACTTGGC39). DRY/AAY was kindly provided by Dr. Laszlo
Hunyady [17]. Constructs were subcloned or inserted into a
modified pCDNA3.1vector containing a FLAG-tag inserted after a
hemagglutinin signal peptide [33]. For Renilla Luciferase (Luc)-
tagged constructs, full length receptors were subcloned into a vector
containing the Luc-tag [34]. For truncated constructs, stop codon
was removed by PCR before insertion into the Luc-tagged
vector (Primer: 59CCTCTAGACTGGATCCAGAGACAGGCT-
TGAGTG39). Mutations were verified by sequencing at Eurofins
MWG Operon.
Cell culture and transfection
COS-7 or HEK293 cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 0.1 mg/mL Genta-
micin (Invitrogen), 0.03% (w/v) L-Glutamine (Substrate Depart-
ment at Panum Institute, Copenhagen, Denmark) and 10% (v/v)
fetal bovine serum (BioChrome AG) in a humidified atmosphere at
37uC and 5% CO2. For transfection, cells were seeded in 10 cm
dishes to obtain 80–90% confluence on the following day, where
cells were transfected. For cell surface expression, competition
binding, and inositol phosphate (IP) accumulation assays, COS-7
cells were transfected with 5 mg plasmid DNA using Lipofecta-
mine2000 (Invitrogen). For b-arrestin2-recruitment, HEK293 cells
were transfected with 1 mg of Luc-tagged AT1R and 3 mgo f
GFP
2-b-arrestin2 using Polyethylenimine (PEI). For b-arrestin2-
recruitment with overexpressed Gaq, HEK293 cells were
transfected with 1 mg of Luc-tagged AT1R and 3 mg of YFP-b-
arrestin2 in combination with 12 mgG aq.
Cell surface expression determined by whole cell ELISA
Transfected cells were seeded for triplicate measures with and
without primary antibody in poly-lysine (Sigma-Aldrich) coated
96-well dishes at 30,000/well in 100 mL growth medium. Assay
was conducted on the following day as described in Bonde et al.,
2010 with minor modifications [35]. In brief, for detection of surface
expressed receptors, cells were incubated with primary antibody (M1
anti-FLAG (Sigma-Aldrich), diluted 1:1000) for 1h at 4uC. Cells
were then fixed, blocked in 1% BSA and incubated with secondary
antibody (HRP-conjugated anti-mouse IgG (GE Healthcare),
diluted 1:3000). For detection of total protein, blocking, primary, and
secondary antibody conditions were conducted in the presence of
0.1% Triton X-100 for permeabilization. Assays were developed
using 3,39,5,59-tetramethylbenzidine (TMB) liquid substrate sys-
tem for ELISA (Sigma-Aldrich). Reactions were stopped with 1M
hydrochloric acid after development of a blue color and
absorbance at 450 nm was measured. Results were analyzed in
GraphPad Prism and Excel. Triplicate means were normalized
firstly by subtraction of values for cells without antibody, and
secondly, by subtraction of values for mock transfected cells.
Whole-cell competitive radio-ligand binding assay
Transfected cells were seeded in poly-lysine coated 48-well
dishes at 100,000 cells/well for triplicate measures. On the
following day, binding assay was conducted as described in
Hansen et al., 2004 [36] with minor modifications. In brief, cells
were incubated at 4uC for 30–60 mins, placed on ice and washed
once in cold Hanks Balanced Salt Solution (HBSS) with 20 mM
Hepes supplemented with 0.9 mM CaCl2 and 1.05 mM MgCl2
(HBSS
+). Cells were incubated for 3h at 4uC with 1nM of
3H-Ang
II (GE Healthcare) and increasing amounts of unlabeled Ang II
diluted in HBSS
+. Cells were washed twice in ice cold HBSS
+ and
lysed in lysis buffer (1% TritonX, 50 mM Tris-HCl pH 7.5,
100 mM NaCl, and 5mM EDTA) at room temperature (RT)
for 30–60 mins of shaking. Well content was transferred to
AT1R Differential Signaling
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scintillation liquid (Perkin Elmer). Total radioactivity was
measured in a TriCarb 2800 TR Liquid Scintillation analyzer
(Perkin Elmer). Results were analyzed in GraphPad Prism and
Excel. Curves were fitted using the non-linear regression analysis
(one-site competition) in GraphPad Prism. KD values for Ang II
were calculated using the equation KD=IC 50-[radioligand].
Statistical analysis, one-way ANOVA with Dunnett’s post-test
against full length WT was performed in GraphPad Prism. For SII
Ang II competition binding,p K i values were calculated based on KD
values for Ang II competition experiments conducted in parallel.
DRY/AAY and N298A mutants (full and truncated) have been
tested in a series of experiments separate from D74N mutants.
Statistics were carried out separately for each set of experiments.
Both datasets were analyzed by repeated measures ANOVA with
subsequent Dunnet’s multiple comparisons test against WT pKi in
GraphPad Prism.
IP accumulation
Transfected cells were seeded in poly-lysine coated 96-well
dishes at 50,000/well in 100 mL DMEM without I-inositol with
Glutamax (Invitrogen) supplemented with 0.1 mg/mL Gentami-
cin (Invitrogen), 10% fetal bovine serum and 2 mCi H
3myo inositol
(Perkin Elmer) pr. mL medium. On the following day, IP assay
was conducted as described in Bonde et al., 2010 [35]. Data were
analyzed in GraphPad Prism and Excel. Statistical analysis was
performed on pEC50 values and fitted maximum values in
GraphPad Prism as described for competition binding above.
DRY/AAY mutants were not included in this analysis. For DRY/
AAY full length and 331D receptors were instead compared using
Figure 3. Cell surface expression determined by ELISA. Cell surface expression (black bars) and total protein levels (white bars) were
determined by whole cell ELISA using M1 anti-FLAG antibody on COS-7 cells transiently transfected with FLAG-tagged rAT1aRs. Total protein levels
were estimated by permeabilizing cells with 0.1% Triton-X100. Data were normalized by first subtracting values for no primary antibody and secondly
subtracting values for mock transfected cells. Data are means and S.E.M.s from at least 5 independent experiments.
doi:10.1371/journal.pone.0014135.g003
Figure 4. Ang II whole cell competition binding. Normalized competition binding curves from experiments using 1nM
3H-Ang II as tracer and
increasing amounts of unlabeled Ang II. Experiments were conducted on COS-7 cells transiently transfected with FLAG-tagged rAT1aRs. WT full
length and truncated receptor curves are shown in bold, curves of truncated receptors are shown as dashed lines. For each receptor, curves were
normalized in GraphPad Prism by defining the fitted bottom value as 0% and top value as 100%. Normalized curves were summarized from at least 3
independent experiments performed in triplicates, means and S.E.M.s are shown. n’s are reported in table 1. Experimental details can be found in the
Materials and Methods section.
doi:10.1371/journal.pone.0014135.g004
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response, fold over minimum response and amplitude (max.-
min. response). Maximum response was calculated as an average
of 0.1 and 1 mM responses, minimum response was the no drug
condition. For the IP accumulation experiments of receptor
mutants with or without Gaq overexpression, pEC50 values for
WT, WT plus Gaq, D74N plus Gaq and Y302F plus Gaq were
compared by repeated measures ANOVA and Dunnett’s post-test
compared to WT plus Gaq in GraphPad Prism.
Bioluminescence Resonance Energy Transfer (BRET)
48 h after transfection, HEK293 cells were washed with PBS,
detached with PBS/Trypsin-EDTA (0.25% Trypsin; 1 mM
EDTA, Invitrogen), harvested by centrifugation (5 mins, 1,000g),
resuspended in PBS supplemented with 0.5 mM Ca
2+ and
0.5 mM Mg
2+ and incubated at room temperature on a shaker
(app. 250 rpm) until the time of the experiments. The resuspended
cells were distributed in 96-well microplates (black/white opti-
plate, PerkinElmer) and incubated in the presence or absence of
ligands. The reading time was 15 mins after agonist addition for
dose-response curves.
DeepBlueC coelenterazine (Coelenterazine 400a, Biosynth) was
added two seconds before reading using an injector at a final
concentration of 5 mM. Measurement of Luc-mediated lumines-
cence and GFP
2-mediated emission from each well were
performed using a Tecan Infinite F500 microplate reader (Tecan
Group Ltd., Ma ¨nnedorf, Switzerland). The BRET2 ratio was
determined by calculating the ratio of the light emitted by GFP
2
(515 nm) over the light emitted by the Renilla Luc (410 nm). For
BRET1, the ratio was determined by calculating the ratio of light
emitted by YFP (530 nm) over the light emitted by the Renilla Luc
(470 nm). The background signal from Luc was determined by co-
expressing the Luc construct with empty vector, and the BRET1/
BRET2 ratio generated from this transfection was subtracted from
all other BRET1/BRET2 ratios. Data were analyzed in
GraphPad Prism and Excel. Statistical analysis was performed in
Excel using Student’s t-test, paired (BRET1 studies) or unpaired
(BRET2 studies), two-tailed.
Results
To obtain new knowledge on the molecular mechanisms
underlying differential signaling, we characterized rat AT1aR
receptor mutants: D74N (2.50), DRY/AAY (3.49–3.51), Y292F
(7.43), N298A (7.49), and Y302F (7.53) in comparison to WT,
either as full length or truncated after serine 331 (331D), see
figure 2. FLAG-tagged constructs were transiently transfected in
COS-7 cells for determination of cell surface expression levels,
ligand binding properties and Gaq/11 dependent signaling by IP
Table 1. Ligand binding.
pKD 6 S.D. N
WT 8.560.2 4
D74N 8.460.04 3
DRY/AAY 8.460.07 3
Y292F 8.460.01 3
N298A 8.660.03 3
Y302F 8.460.05 3
WT 331D 8.560.03 3
D74N 331D 8.560.06 3
DRY/AAY 331D 8.560.2 3
Y292F 331D 8.560.06 3
N298A 331D 8.760.05 3
Y302F 331D 8.560.08 3
Ang II affinity: pKD values, standard deviations and n’s from whole cell
competition binding assay using 1nM
3H-Ang II as tracer and increasing
amounts of unlabeled Ang II. Experiments were conducted on COS-7 cells
transiently transfected with FLAG-tagged rAT1aRs in triplicate setups.
Experimental details can be found in the Material and Methods section.
Statistical significance was probed by one-way ANOVA and subsequent
Dunnett’s post-test against full length WT receptor values and no significant
differences (p,0.05) were found.
doi:10.1371/journal.pone.0014135.t001
Figure 5. Ang II induced IP accumulation. A, B, and C: Dose-
response curves normalized to the fitted maximum for WT AT1R
compiled from at least 5 independent experiments performed in
triplicates (mean and S.E.M.). WT and WT 331D have been included on
all graphs for comparison. A: D74N. B: DRY/AAY. C: Receptor mutants:
Y292F, N298A, and Y302F. Experiments were conducted on COS-7 cells
transiently transfected with FLAG-tagged rAT1aR. WT full length and
truncated receptor curves are shown in bold, curves of truncated
receptors are shown as dotted lines. Experimental details can be found
in the Material and Methods section. n’s are reported in table 2.
N.D.=no drug.
doi:10.1371/journal.pone.0014135.g005
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FLAG-tagged constructs were fused with Renilla Luc and
transiently expressed in HEK293 cells along with GFP
2-tagged
b-arrestin2. In addition, the effect of overexpression of b-arrestin2
and Gaq protein on b-arrestin2 recruitment and G protein-
dependent signaling was evaluated in transiently transfected
HEK293 cells.
Cell surface expression
Cell surface expression levels were determined by whole cell
ELISA using an antibody directed against the N-terminal FLAG-
tag of the receptor. Results are reported in figure 3. For the full
length receptors, D74N and DRY/AAY are expressed at similar
levels as WT (mean 6 S.E.M.: 0.04660.004, n=10) while Y292F
and N298A show reduced expression (0.03760.007 and
0.03360.004, respectively, both n=5). The Y302F mutant has a
tendency to slightly higher surface expression than WT
(0.05760.007, n=5). Truncated constructs generally display
lower expression; about half of full length WT. This was similar
to what previously has been found for truncated AT1Rs [28,37].
Again, the truncated Y292F and N298A constructs have slightly
lower values compared to WT 331D while the levels of Y302F
331D are slightly higher than WT 331D. The total protein levels
vary among receptor mutants. However, the general trend is that
truncated receptors show higher levels of total protein than the full
length receptors. Based on competition binding studies, we have
calculated the Bmax for the WT AT1R to be 2465 fmol/10
5 cells
(mean and S.D., n=3).
Ang II affinity
Affinity for the endogenous agonist Ang II was determined by
whole cell competition binding using tracer amounts of
3H-Ang II
and increasing amounts of unlabeled Ang II. Normalized curves
are depicted in figure 4 and pKD values are reported in table 1.
The WT receptor has a pKD of 8.560.2 (mean and S.D., n=4).
As illustrated, all of the mutants show similar affinities for Ang II
compared to WT in this assay, and truncation does not appear to
affect the affinity.
Ang II induced G protein-dependent signaling
Ang II dose-response curves for IP accumulation of WT and
mutant receptor constructs were determined. Summarized nor-
malized curves are depicted in figure 5A–C, while pEC50 values
are reported in table 2. As shown in figure 5B, the DRY/AAY is
the only mutant, which appears practically abrogated in signaling
capacity. pEC50 values for full length mutant receptors (except
DRY/AAY, which was not possible to analyze) are significantly
lower than WT (EC50 ratio 0.2–0.5, n.5, p,0.05). This supports
previous reports of impaired signaling for these receptor mutants
[12,16,17,18,19,20,30,31]. Mutant 331D receptors show increased
pEC50 values (,2–4 fold change from full length) hereby showing
potency similar to full length WT. None of them, however, have
improvements comparable to WT 331D, which has a significantly
increased potency (EC50 ratio 2.6, p,0.05 compared to WT).
When comparing the fitted maximum values, only D74N and
N298A are significantly reduced compared to WT (DRY/AAY
mutants were not included in this test due to their lack of
response). The DRY/AAY mutant shows abrogated signaling
through the Gaq/11 dependent pathway (figures 5B). Signaling
response - as determined by amplitude and fold over N.D. - is
slightly, yet significantly increased upon truncation. However, we
found no significant difference in maximum values for full length
vs. 331D receptor mutants, and the response of the DRY/AAY
331D is still much reduced compared to WT. This indicates that
this mutant is more G protein ‘‘uncoupled’’ than the other
mutants.
In summary, mutant receptors are all impaired in the IP
accumulation assay, however, not to the same degree. Truncation
increases potency and efficacy indicating that desensitization is
involved in the impaired response, but is not completely able to
rescue the phenotype of these mutants. Also, only the DRY/AAY
mutant appears severely impaired in signaling in our setup.
b-arrestin2 recruitment in response to Ang II
To study the ability of mutant receptors to recruit b-arrestin2,
we co-transfected C-terminally Luc-tagged AT1R constructs with
N-terminally GFP
2-tagged b-arrestin2 and studied ligand-induced
association between the molecules using a BRET assay. Compiled
curves are depicted in figures 6A–C and pEC50 and maximum
response values in table 3. For the WT receptor, Ang II induces a
robust dose-dependent recruitment, which is impaired in potency
and efficacy for the truncated WT construct (ratios 0.3 and 0.8
compared to full length, respectively). Somewhat unexpectedly,
only the DRY/AAY mutant has similar potency as WT while the
others are impaired (ratios 0.2–0.4) compared to WT (p,0.05).
Truncation only affects Ang II potency for the D74N mutant –
which actually is more potent than the full length receptor.
Truncation, however, significantly impairs maximal responses of
the receptor mutants (ratios 0.6-0.8). All of the full length receptor
mutants except N298A show maximum responses similar to WT
in the b-arrestin2 recruitment assay, see figure 6A–C and table 3.
SII Ang II induced b-arrestin2 recruitment
Previous studies of G protein-independent b-arrestin recruit-
ment using SII Ang II has shown that this recruitment is weaker
than for Ang II (,60%), most likely because G protein activation
increases the ability of the receptor to recruit b-arrestins [34,38].
Since all of our mutants are impaired in G protein-dependent
signaling, this might be the reason why the potency of Ang II
Table 2. Ang II induced IP accumulation.
Receptor pEC50 ± S.D.
Fold change
compared to WT N
WT 9.160.2 - 10
D74N 8.560.1* 0.2 5
DRY/AAY N.A. N.A. 5
Y292F 8.860.1* 0.5 5
N298A 8.660.1* 0.3 5
Y302F 8.860.2* 0.5 5
WT 331D 9.560.1* 2.6 9
D74N 331D 9.160.1 0.9 5
DRY/AAY 331D N.A. N.A. 5
Y292F 331D 9.360.1 1.4 5
N298A 331D 9.260.1 1.2 5
Y302F 331D 9.160.2 1 5
pEC50 values and standard deviations from dose-response curves of induced IP
accumulation on COS-7 cells transiently transfected with FLAG-tagged rAT1aRs
stimulated with Ang II for 45 mins. Fold change values of EC50 are reported for
comparison between WT and mutant receptors. Data are summarized from at
least 5 independent experiments performed in triplicates. Experimental details
can be found in the Material and Methods section.
*indicates p,0.05 determined by one-way ANOVA and subsequent Dunnett’s
post-test against full length WT receptor values.
doi:10.1371/journal.pone.0014135.t002
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We therefore measured dose-response curves of SII Ang II
induced b-arrestin2 recruitment (table 3 and figures 6D–F). This
characterization reveals three very interesting phenotypes for the
mutants. The D74N mutant has significantly increased potency (,23
fold) and maximum response (,1.3 fold) compared to WT
(figure 6D). The DRY/AAY and N298A mutants show significantly
increased potencies for SII Ang, but maximum responses similar to
WT (figure 6E). Receptor mutants Y292F and Y302F are substantially
impaired in recruitment of b-arrestin2 in response to SII Ang II
(figure 6F). The truncated mutants generally follow the tendencies
of their full length equivalents (data not shown).
SII Ang II induced IP accumulation
To ensure that the increased signaling capabilities of the
m u t a n t sc o m p a r e dt oW Tr e c eptor was specific for b-arrestin2
recruitment, we tested dose-response properties of the receptor
mutants D74N, DRY/AAY, N298A in the IP assay (figure 7
(WT, D74N and DRY/AAY) and Figure S1 (N298A)). As
previously reported, SII Ang II does not induce signaling from
WT [21], nor do the D74N and N298A mutants respond to this
ligand. Truncation increases the signaling response for all
constructs tested. Interestingly, SII Ang II appears to be slightly
more efficacious on the DRY/AAY mutant full length and
truncated than on the WT and D74N, when looking at the
response over ‘‘baseline’’, figure 7B. The maximum response is,
however, still much lower than that of WT in response to
Ang II.
SII Ang II affinity
To investigate whether the increased potency of SII Ang II for
the mutants D74N, DRY/AAY and N298A was caused by
increased affinity for SII Ang II, we studied SII Ang II affinity by
heterologous competition binding using tracer amounts of
3H-Ang
II and unlabeled SII Ang II. Results are reported in figure 8 and
table 4. We found that all three mutants show significantly
increased affinity for SII Ang II compared to the WT in the range
of 3–5.5 fold.
Effect of b-arrestin and G protein overexpression on IP
accumulation and b-arrestin2 recruitment
To further test our hypothesis that a biased signaling phenotype
can result from competition between signaling pathways rather
than direct inability to interact with a given downstream signaling
Figure 6. b-arrestin2 recruitment by BRET. Dose-response curves normalized to the fitted maximum for WT AT1R stimulated with Ang II
compiled from at least 4 independent experiments performed in duplicate (mean and S.E.M.). All values are shown as percent of the maximal
response with Ang II on WT AT1R. WT AT1R and WT 331D AT1R have been included on graphs for comparison. A–C: Stimulation with AngII. C, D–F:
Stimulation with SII Ang II. A: D74N. B: DRY/AAY. C: Y292F, N298A, and Y302F. D: D74N. E: Receptor mutants: DRY/AAY and N298A. F: Receptor
mutants: Y292F and Y302F. Experiments were conducted on HEK293 cells transiently co-transfected with Luc-tagged rAT1aRs in combination with
GFP2-tagged b-arrestin2. Curves of full length receptors are shown as full lines, and curves of truncated receptors are shown as dashed lines. WT full
length and truncated receptor curves are shown in bold. N.D.=no drug. Experimental details can be found in the Material and Methods section. n’s
are reported in table 3.
doi:10.1371/journal.pone.0014135.g006
AT1R Differential Signaling
PLoS ONE | www.plosone.org 7 November 2010 | Volume 5 | Issue 11 | e14135molecule, we tested the effect of G protein overexpression in
HEK293 cells transiently transfected with receptors and b-
arrestin2 in amounts typically used to measure b-arrestin2-
recruitment with BRET1.
Data on b-arrestin2-recruitment in response to Ang II are
reported in figure 9. The WT receptor shows similar or slightly
lower response with overexpression of Gaq. The D74N mutant
shows a tendency towards increase in response upon Gaq
overexpression compared to WT, while the difference response
for the Y302F mutant is significantly greater than for the WT
(0.01360.0006 vs. -0.00860.006, mean and S.E.M., n=4). In
contrast, the difference in response upon G protein overexpression
is not very large for the DRY/AAY mutant – again supporting
that this mutant has a conformation different from the other
receptor mutants.
When looking at G protein-dependent signaling depicted in
figure 10, signaling is drastically impaired by the overexpression of
b-arrestin2. Overexpression of Gaq protein increases Ang II-
induced signaling for all of the tested receptors except the DRY/
AAY mutant, which remains practically uncoupled. In the cells
overexpressing G protein, the D74N mutant still has a pEC50
value significantly lower than the WT (D74N 8.660.1 vs. WT
9.060.2; mean and S.D., n=4), while the Y302F is not
significantly different though there is a trend towards it being
lower than the WT (8.860.1, n=4). Similarly, there is a tendency
towards increased pEC50 for the WT receptor upon G protein
overexpression (8.760.3), which is also not statistically significant.
Hereby, these results are similar to the IP accumulation data for
full length and truncated constructs and further support that
different mechanisms of G protein uncoupling exist. For SII Ang II
stimulation, signaling is slightly increased (basal levels and
responsiveness) for WT, DRY/AAY and Y302F mutants upon
overexpression of G protein, see figure S2. However, efficacy
remains practically nonexistent.
Discussion
In this study, we investigated the mechanistic background of five
AT1R receptor mutants previously published to be biased towards
G protein-independent pathways. We characterized their signaling
through Gaq/11 versus b-arrestin2 in response to Ang II and SII
Ang II and probed of the effect of their stable interaction with b-
arrestins on their signaling phenotypes. Also, we tested the effect of
overexpression of intracellular signaling partners for select
mutants. The results strongly support our hypothesis that the
receptor mutants are uncoupled from G protein-dependent
signaling by principally different mechanisms, which are most
likely caused by distinct conformational states. We have sought to
summarize the hypothetical conformations induced by the
different mutations in figure 11.
Based on our results, the mutants can be categorized into four
different groups discussed below. First, the DRY/AAY mutant is
severely impaired in Ang II induced G protein-dependent signaling,
which is not reversed upon truncation or overexpression of G
protein. Thisfindingis in good correspondencewith other studies of
theAT1R[12,17,39,40,41,42].Thecrystalstructureofopsinbound
to a peptide derived from the C-terminal of transducin suggests that
R3.50 (of the DRY motif) is important for the interaction with G
protein while the D3.49 is important for the transition between
inactive and active states [43]. In contrast, the receptor mutant
shows robust increased potency for SII Ang II in the b-arrestin2
recruitment assay, which is likely explained by its increased affinity
for SII Ang II, but could also suggest a bias towards b-arrestin-
dependent signaling, as discussed below. Surprisingly the mutant
appeared more prone to SII Ang II activated signaling through
Gaq/11 than WT suggesting that the conformations induced by SII
Ang II and by the DRY/AAY mutation are not the same and can
partly complement each other.Hereby,italsodemonstrates that the
DRY motif is not absolutely necessary for AT1R mediated
Table 3. b-arrestin2 recruitment measured by BRET.
b-arrestin2 recruitment Ang II SII Ang II
pEC50 Fold change
Maximum
Response n pEC50
Fold
change
Maximum
response n
WT 8.460.2 - 0.2060.03 5 6.560.2 - 0.1560.02 4
D74N 7.960.1* 0.4 0.2060.02 5 7.860.3* 23 0.1960.02* 5
DRY/AAY 8.260.1 0.7 0.1860.02 5 7.560.1* 11 0.1560.01 4
Y292F 7.960.3* 0.4 0.1760.01 5 N.R. - N.R. 5
N298A 7.760.5* 0.2 0.1760.01* 5 7.960.2* 23 0.1560.02 4
Y302F 7.760.2* 0.2 0.1960.01 5 N.R. - N.R. 5
WT 331D 7.860.2* 0.3 0.1660.01* 4 6.660.3 1.3 0.1260.02* 5
D74N 331D 8.160.11 0.6 0.1460.02*1 47 . 5 60.2* 11 0.1560.021 5
DRY/AAY 331D 8.260.3 0.7 0.1560.03*1 47 . 0 60.3{ 3.6{ 0.1560.03 4
Y292F 331D 7.760.2* 0.2 0.1160.01*1 4 N.R. - N.R. 5
N298A 331D 7.660.1* 0.2 0.1260.01*1 47 . 1 60.3{ 4.3{ 0.1260.01 4
Y302F 331D 7.660.2* 0.2 0.1260.01*1 4 N.R. - N.R. 5
pEC50 values and standard deviations from dose response curves of ligand induced b-arrestin2 recruitment on HEK293 cells transiently co-transfected with Luc-tagged
rAT1aRs and GFP
2-tagged b-arrestin2 stimulated with Ang II or SII Ang II for 15 minutes. Fold change EC50 values compared to full length WT receptor are reported.
Maximum response and standard deviations reported from dose response curves. Data are summarized from at least 4 independent experiments performed in
duplicates. Experimental details can be found in the Material and Methods section.
*indicates p,0.05 determined by two-tailed Student’s t-test against full length WT receptor values.
1indicates p,0.05 determined by two-tailed Student’s t-test against the full length version of WT/mutant receptor.
{pEC50 values for DRY/AAY 331D and N298A 331D with SII Ang II are determined from normalized dose-response curves. Fold responses of these two receptor mutants
are determined from the WT pEC50 values for normalized curves of SII Ang II: 6.560.3 for full length and 5.860.3 for 331D.
doi:10.1371/journal.pone.0014135.t003
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activation was still very low and we did not observe this in the
overexpression experiments. Thus, further studies will be needed to
clarify the exact mechanisms involved.
Second, the D74N mutant shows impaired G protein-dependent
signaling, which is restored to full length WT levels upon
truncation, and shows .20 fold increased potency and increased
efficacy for b-arrestin2 recruitment in response to SII AngII. This
is not accompanied by a change in potency and efficacy for SII
Ang II signaling through Gaq/11. We propose that at least part of
the mechanism underlying this phenotype is a relative preference
for b-arrestin2 recruitment rather than inability to interact with G
protein. The mutant shows increased affinity for SII Ang II, which
is in agreement with previous studies [16]. However, we do not
believe that the increased binding affinity for SII Ang II can fully
explain the changes in potency/efficacy profiles for SII Ang II in
the BRET vs. IP accumulation assay. Indeed, the increased affinity
for peptide analogues and the decreased affinity for inverse
agonists previously reported for D74 mutants may reflect that the
mutant shows constitutive association with b-arrestin2, which has
been reported to form a high affinity ternary complex, similar to
the G protein bound receptor state [44,45]. Further studies will be
needed to confirm this.
Third, the N298A mutant is moderately impaired in signaling
through Gaq/11 showing WT-like efficacy when normalized to
surface expression. The receptor mutant shows increased potency
for SII Ang II induced b-arrestin2 recruitment and increased SII
Ang II affinity similar to what was found for the DRY/AAY
mutant. This mutant does not show any Gaq/11 induced signaling
in response to SII Ang II. Fourth, Y292F and Y302F mutants display
moderately impaired G protein-dependent signaling, and severely
impaired recruitment of b-arrestin2 in response to SII Ang II. This
could suggest that SII Ang II induces a conformation in these
mutations that is different from that of the WT and the two other
mutations. Murine AT1aR Y292F has previously been found
unable to induce ERK1/2 phosphorylation in response to SII Ang
II [46], which is in good agreement with our findings. The authors
suggest that Y292 (7.43) is required for SII Ang II to induce the
conformation able to activate ERK1/2, which appears to be
extendable to b-arrestin2 recruitment. Our studies suggest that the
Y302F mutation may have a similar function.
Previous studies have shown severely compromised G protein-
dependent signaling of some of the mutant receptors
[16,18,30,31], while we find most of them to be only moderately
impaired. This discrepancy is most likely due to differences in the
method for detection of IP accumulation such as time of
stimulation, which is shorter in the aforementioned studies. It is
likely that this also reflect impaired kinetics of these receptor
mutants compared to WT [17]. Cellular levels of receptors and
signaling components such as b-arrestins may also contribute to
Figure 7. SII Ang II induced IP accumulation. A: Dose-response curves normalized to the fitted maximum response for WT AT1R compiled from
at least 3 independent experiments performed in triplicates (mean and S.E.M.). B: Dose-response curves normalized to no drug (N.D.) response for the
full length receptor. In this graph, one data set for DRY/AAY 331D had to be left out due to missing values for full length DRY/AAY on that particular
assay date. Experimental setup as in figure 5.
doi:10.1371/journal.pone.0014135.g007
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phenotypes of the receptor mutants yielding only the DRY/AAY
mutant as abrogated in Ang II induced G protein-dependent
signaling and largely unaffected by truncation as well as
overexpression of G protein.
The BRET assay offers the possibility of studying protein-
protein interactions in response to ligands in live cells. However,
there are certain caveats to the assay that have to be considered. It
is not possible to distinguish between signal from receptors being
functionally expressed on the surface and receptors trapped in the
ER during biosynthesis, which can be a problem for receptor
mutants. This can lead to a false decrease in BRET ratios affecting
both potency and efficacy. However, this does not necessarily
affect the observed potency changes observed for Ang II and SII
Ang II for the different mutations. Maximum responses in the
BRET assay must also be interpreted carefully since this response
is very sensitive to conformational changes of the receptor-Luc
molecule, which could be introduced by the truncation and
mutation. Yet, the importance of the C-terminal tail of the AT1R
in b-arrestin recruitment has been demonstrated several times in
the literature using other methods to detect the receptor-b-arrestin
interactions [27,29,47].
Differential activation of signaling pathways can also be
mediated at the cellular level by the availability of implicated
signaling proteins and the kinetics of activation of the different
signaling pathways [48]. Thus, these factors are important to take
into account when interpreting data on biased signaling. In our
studies, we have studied G protein-dependent activation of the
inositol phosphate signaling pathway. IP accumulation provides a
good measure of G protein activation. However, there may be
certain pitfalls in measuring a downstream signaling pathway
instead of direct receptor-G protein interaction, and such an
analysis could provide additional insights to the mechanisms
involved. On a similar note, characterization of G protein-
independent signaling pathways, e.g. ERK1/2 activation, would
also provide interesting insights to the different phenotypes of the
receptor mutants. Though it is well-established that recruitment of
b-arrestin2 facilitates ERK1/2 activation for the AT1R, b-
Figure 8. SII Ang II affinity. Normalized competition binding curves from experiments using 1nM
3H-Ang II as tracer and increasing amounts of
unlabeled SII Ang II. Experiments were conducted on COS-7 cells transiently transfected with FLAG-tagged rAT1aRs. WT full length and truncated
receptor curves are shown in bold, curves of truncated receptors are shown as dashed lines. For each receptor, curves were normalized in GraphPad
Prism by defining the fitted bottom value as 0% and top value as 100%. Normalized curves were summarized from at least 3 independent
experiments performed in triplicates, means and S.E.M.s are shown. pKi values and n’s are reported in table 4. Experimental details can be found in
the Material and Methods section. A: WT and D74N. B: DRY/AAY and N298A.
doi:10.1371/journal.pone.0014135.g008
AT1R Differential Signaling
PLoS ONE | www.plosone.org 10 November 2010 | Volume 5 | Issue 11 | e14135arrestin2 recruitment does not necessarily reflect activation of b-
arrestin-arrestin dependent signaling [7]. Such studies are,
however, easily complicated since by the complex nature of G
protein-independent signaling, which remains to be fully mapped
[49,50], just as both dose and stimulation time required to yield
the maximal response could be affected by mutation.
Though it is now generally recognized that multiple signaling
conformationsexistandmaybephysiologicallyrelevantforanumber
of 7TMRs [1,6], the molecular determinants underlying specific G
protein or b-arrestin interactions remain largely unresolved.
With the exception of the Y292 (7.43) residue, the residues
included in this study are all highly conserved in Family A 7TMRs
[51]. The residues are proposed to form polar interactions
involving water molecules that are important for receptor
activation, including interaction between positions 2.50 (D74)
and 7.49 (N298A) based on evidence from crystal structures, but
also a number of mutational studies including one of the AT1R
[52,53,54,55,56,57,58]. Except for the DRY motif, which is now
fairly recognized as being specifically important for G protein-
coupling, the data on G protein-independent pathways or
desensitization for the remaining mutants is scarce for other
7TMRs. Mutation of residues in the NPXXY motif were found to
impair signaling as well as internalization in the b2-adrenergic
receptor [59]. Correspondingly, in the Formyl Peptide Receptor
mutations of D2.50 and N7.49 inhibited internalization and b-
Figure 9. b-arrestin2 recruitment with G protein overexpression. Dose-response curves of Ang II-induced b-arrestin2 recruitment determined
by BRET1. Normalized curves compiled from four independent experiments performed in triplicates and standard errors are shown. Differences in
response between cells overexpressing Gaq protein or not were measured by BRET1. Response is defined as: no drug value subtracted from average
of 10
26 and 10
25 M Ang II values. * indicates p,0.05 determined by paired Student’s t-test to WT values.
doi:10.1371/journal.pone.0014135.g009
Table 4. Whole cell competition binding – SII Ang II.
SII Ang II pKi±S.D. n
Fold change
to WT
WT 5.960.09 4 -
D74N 6.660.06* 4 5.5
DRY/AAY 6.160.2* 3 3.0
N298A 6.260.04* 3 4.1
WT 331D 6.060.08* 4 1.4
D74N 331D 6.860.06* 4 7.8
DRY/AAY 331D 6.260.2* 3 4.0
N298A 331D 6.260.06* 3 4.0
pKi values have been calculated based on KD values for homologous
competition with Ang II executed in parallel with the SII Ang II experiments.
DRY/AAY and N298A mutants (full and truncated) have been tested in a series
of experiments separate from D74N mutants. WT pKi (full and 331D) are
reported for D74N series in the table. For the experiments with DRY/AAY and
N298A mutants WT pKi was: 5.660.1 (mean and S.D., n=3). Statistics were
carried out separately for each set of experiments. Both datasets were analyzed
by repeated measures ANOVA with subsequent Dunnet’s multiple comparisons
test against WT pKi in GraphPad Prism.
*indicates P,0.05.
doi:10.1371/journal.pone.0014135.t004
AT1R Differential Signaling
PLoS ONE | www.plosone.org 11 November 2010 | Volume 5 | Issue 11 | e14135arrestin recruitment [60]. Here, we found different phenotypes for
the N7.49 and the Y7.53 receptor mutants, N7.49 showing
increased potency of SII Ang II induced b-arrestin2 recruitment
and Y7.53 being impaired for this function. The existing crystal
structures suggest an important function of Y7.53 as a rotameric
switch that participates in an aromatic interaction with helix 8 in
inactive rhodopsin [3,4,61]. This amino acid is part of an
interhelical hydrogen-bonding network in the ‘‘non-rhodopsin’’
structures, and is involved in keeping TM6 in its outward position
in the structures of opsin. Further studies will be needed to the
exact roles of the TM2 and TM7 residues in induction of
differentially activating phenotypes.
The concept of differential signaling or biased agonism
challenges the traditional understanding of how 7TMRs exert
their physiological roles and offers the possibility to develop novel
treatment options selectively targeting specific signaling pathways.
Figure 10. IP accumulation with overexpression of b-arrestin2 and G protein. Dose-response curves of Ang II stimulation normalized to the
fitted maximum for WT AT1R plus G protein compiled from four independent experiments performed in triplicates (mean and S.E.M.). WT has been
included on all graphs for comparison. A: D74N. B: DRY/AAY. C: Y302F. Experiments were conducted on transiently transfected HEK293 cells.
N.D.=no drug.
doi:10.1371/journal.pone.0014135.g010
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mechanisms behind the phenomenon. Our study proposes that
selective G protein-uncoupling leading to selective b-arrestin-
dependent signaling can occur both through specific conforma-
tions lacking epitopes necessary for G protein-coupling and
through conformations with a ‘‘gain of function’’ for b-arrestin
recruitment compared to WT. Since induction of such different
conformations by external ligands in an in vivo setting might not
lead to similar outcomes, it will be of utmost importance to be
able to distinguish between such conformations at the molecular
level. Another interesting perspective to this study is that lack of
epitopes important for G protein-coupling can be at least partially
compensated in certain settings -exemplified in our study by the
effects of SII Ang II on the DRY/AAY mutant. This latter
finding is in good agreement with the current theory of 7TMR
activation being mediated by different micro-switches working
together in an allosteric fashion [3]. Further studies of the
molecular mechanisms underlying biased agonism and develop-
ment of more biased agonists will be needed to address these
issues.
In conclusion, even seemingly similar phenotypes in differ-
ential signaling may represent principally different mechanisms
of G protein-uncoupling, which again are most likely caused by
distinct conformational states. We show how a strong interac-
tion with b-arrestin2 might affect G protein-dependent signaling
responses. Hereby, the results obtained in this study have
implications for the design and interpretation of future studies
of the molecular determinants of differential signaling of
7TMRs.
Supporting Information
Figure S1 SII Ang II induced IP accumulation. A: Dose-
response curves of IP accumulation from N298A mutants
normalized to the fitted WT Ang II induced maximum response.
B: Curves normalized to full length no drug (N.D.) response. WT
Ang II has been included as a control in bold. Dashed line
indicates truncated receptor. Experimental setup as in figure 5.
Found at: doi:10.1371/journal.pone.0014135.s001 (1.13 MB EPS)
Figure S2 IP accumulation with overexpression of b-arrestin2
and G protein. Dose-response curves of SII Ang II stimulation
normalized to fitted maximum WT plus G protein Ang II
compiled from three independent experiments performed in
triplicates. WT curves have been included on all graphs for
comparison. Dashed lines indicate overexpression of Gaq protein.
Experiments were performed on transiently transfected HEK293
cells.
Found at: doi:10.1371/journal.pone.0014135.s002 (1.41 MB EPS)
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Figure 11. Schematic overview of different phenotypes of the mutants. Schematic presentation of how the residues mutated in this study
could hypothetically affect the induction of different conformations. These interpretations are based on the data included in this study and should be
considered with the precautions mentioned in the Discussion section.
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